Skip to main content
Erschienen in: Journal of Clinical Immunology 3/2007

01.05.2007 | Original Paper

CD4 +CD25 + Regulatory T Cells Decreased the Antitumor Activity of Cytokine-Induced Killer (CIK) Cells of Lung Cancer Patients

verfasst von: Hui Li, Jin-Pu Yu, Shui Cao, Feng Wei, Peng Zhang, Xiu-Mei An, Zong-Tang Huang, Xiu-Bao Ren

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

 

CD4 +CD25 + regulatory T cells (Tregs) have been shown to inhibit cytotoxic lymphocytes-mediated immune responses. Cytokine-induced killer (CIK) cells exert high impact on adoptive immunotherapeutic approaches. Therefore, the purpose of this report was to determine the effect of Tregs on CIK cell growth and CIK-induced cytotoxicity for inhibition of tumor growth in vivo as well as in vitro. After depletion of CD4 +CD25 + cells before culture, the proliferation and cytotoxicity of CIK cells, which indicated in bromodeoxyuridine (BrdU) and lactic dehydrogenase (LDH) assays, were significantly increased. Depletion of CD4 +CD25 + cells preculture also enhanced the suppression effect on the lung cancer cells inoculated in experimental animals. Blockage of glucocorticoid-induced tumor necrosis factor receptor (GITR) and transforming growth factor β1 (TGF-β1) by antibodies partially abrogated the suppressive effect of CD4 +CD25 + cells on CIK. These results indicated that Tregs could inhibit the antitumor activity of CIK cells. The molecules TGF-β and GITR may contribute to the suppressive function of CD4 +CD25 + cells.
Literatur
1.
Zurück zum Zitat Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562, 2004PubMedCrossRef Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562, 2004PubMedCrossRef
2.
Zurück zum Zitat Antony PA, Piccirillo CA, Akpinarli A, et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601, 2005PubMed Antony PA, Piccirillo CA, Akpinarli A, et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601, 2005PubMed
3.
Zurück zum Zitat Smyth MJ, Teng MW, Swann J, et al.: CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176:1582–1587, 2006PubMed Smyth MJ, Teng MW, Swann J, et al.: CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176:1582–1587, 2006PubMed
4.
Zurück zum Zitat Azuma T, Takahashi T, Kunisato A, et al.: Human CD4+CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63:4516–4520, 2003PubMed Azuma T, Takahashi T, Kunisato A, et al.: Human CD4+CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63:4516–4520, 2003PubMed
5.
Zurück zum Zitat Knutson KL, Dang Y, Lu H, et al.: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177:84–91, 2006PubMed Knutson KL, Dang Y, Lu H, et al.: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177:84–91, 2006PubMed
6.
Zurück zum Zitat Taieb J, Chaput N, Schartz N, et al.: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722–2729, 2006PubMed Taieb J, Chaput N, Schartz N, et al.: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722–2729, 2006PubMed
7.
Zurück zum Zitat Leemhuis T, Wells S, Scheffold C, et al.: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181–187, 2005PubMedCrossRef Leemhuis T, Wells S, Scheffold C, et al.: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181–187, 2005PubMedCrossRef
8.
Zurück zum Zitat Zhang YS, Yuan FJ, Jia GF, et al.: CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11:3339–45, 2005PubMed Zhang YS, Yuan FJ, Jia GF, et al.: CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11:3339–45, 2005PubMed
9.
Zurück zum Zitat Ren X, Yu J, Liu H, et al.: Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biotherapy & Radiopharmaceuticals 2006; 21(1):22–33 Ren X, Yu J, Liu H, et al.: Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biotherapy & Radiopharmaceuticals 2006; 21(1):22–33
10.
Zurück zum Zitat Schmidt-Wolf IGH, Lefterova P, Mehta BA, et al.: Phenotypic characterization and identification effector cells involved in tumor cells recognition of cytokine-induced killer cells. Exp Haematol 21:1673–1679, 1993 Schmidt-Wolf IGH, Lefterova P, Mehta BA, et al.: Phenotypic characterization and identification effector cells involved in tumor cells recognition of cytokine-induced killer cells. Exp Haematol 21:1673–1679, 1993
11.
Zurück zum Zitat Khazaie K, von Boehmer H: The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16:124–136, 2006PubMedCrossRef Khazaie K, von Boehmer H: The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16:124–136, 2006PubMedCrossRef
12.
Zurück zum Zitat Comes A, Rosso O, Orengo AM, et al.: CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176:1750–1758, 2006PubMed Comes A, Rosso O, Orengo AM, et al.: CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176:1750–1758, 2006PubMed
13.
Zurück zum Zitat Chakraborty NG, Chattopadhyay S, Mehrotra S, et al.: Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794–802, 2004PubMedCrossRef Chakraborty NG, Chattopadhyay S, Mehrotra S, et al.: Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794–802, 2004PubMedCrossRef
14.
Zurück zum Zitat Kanamaru F, Youngnak P, Hashiguchi M, et al.: Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 172:7306–7314, 2004PubMed Kanamaru F, Youngnak P, Hashiguchi M, et al.: Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 172:7306–7314, 2004PubMed
15.
Zurück zum Zitat Chen WJ, Wahl SM: TGF-b: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14:85–89, 2003PubMedCrossRef Chen WJ, Wahl SM: TGF-b: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 14:85–89, 2003PubMedCrossRef
16.
Zurück zum Zitat Marie JC, Letterio JJ, Gavin M, et al.: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201(7):1061–1067, 2005PubMedCrossRef Marie JC, Letterio JJ, Gavin M, et al.: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201(7):1061–1067, 2005PubMedCrossRef
17.
Zurück zum Zitat Birebent B, Lorho R, Lechartier H, et al.: Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 34:3485–3496, 2004PubMedCrossRef Birebent B, Lorho R, Lechartier H, et al.: Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 34:3485–3496, 2004PubMedCrossRef
Metadaten
Titel
CD4 +CD25 + Regulatory T Cells Decreased the Antitumor Activity of Cytokine-Induced Killer (CIK) Cells of Lung Cancer Patients
verfasst von
Hui Li
Jin-Pu Yu
Shui Cao
Feng Wei
Peng Zhang
Xiu-Mei An
Zong-Tang Huang
Xiu-Bao Ren
Publikationsdatum
01.05.2007
Erschienen in
Journal of Clinical Immunology / Ausgabe 3/2007
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-007-9076-0

Weitere Artikel der Ausgabe 3/2007

Journal of Clinical Immunology 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.